# A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

> **NCT07269210** · PHASE2 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 60 (estimated)

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Solbinsiran
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07269210
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2027-03
- **Final completion:** 2027-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07269210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07269210, "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07269210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*